LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes

Phase 3CompletedNCT00214630

AstraZeneca825 enrolled

Overview

Comparison of rosuvastatin and atorvastatin in subjects with acute coronary syndromes

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

825

Conditions

Acute Coronary Syndromes

Interventions

rosuvastatin calciumDRUG

atorvastatinDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Non-ST segment elevation ACS and ST segment elevation ACS who receive optimal reperfusion therapy Exclusion Criteria: * Previous Q-wave infarct within the last 4 weeks * CK elevation not caused by myocardial injury * uncontrolled hypertension at time of randomization

Locations (56)

Outcomes

Primary Outcomes

Reduction of LDL-C following 12 weeks of treatment

Secondary Outcomes

% change from baseline in LDL-C following 2 & 6 weeks of treatment; % change from baseline in TC, HDL-C, triglycerides, non-HDL-C, apolipoprotein A-1, apolipoprotein B, LDL-C/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, ApoB/Apo A-1 @ weeks 6 & 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

Research Site

San Diego, California, United States

Research Site

Torrance, California, United States

Research Site

Bridgeport, Connecticut, United States

Research Site

Atlantis, Florida, United States

Research Site

Brandon, Florida, United States

Research Site

Jacksonville, Florida, United States

Research Site

Pensacola, Florida, United States

Research Site

Safety Harbor, Florida, United States

Research Site

Tampa, Florida, United States

Research Site

Aurora, Illinois, United States

...and 46 more locations